Neuroscience treatments shape ACADIA Pharmaceuticals' (NASDAQ:ACAD) story because the company has moved past the milestone that defines most biotechs, its first drug approval, and now faces the different and in some ways harder task of building a durable commercialBusinesswhile continuing to advance new candidates. …
ABVC BioPharma (NASDAQ:ABVC) is a nano-cap drug developer spreading limited resources across several early- and mid-stage programs, betting that at least one can advance far enough to attract a meaningful licensing deal with a larger pharmaceutical partner. That licensing-focused model is a deliberate response …
Abacus Global Management (NYSE:ABX) brings an unusual asset class to public markets because its core business is life settlements, buying life-insurance policies from the individuals who own them, paying a lump sum, taking over the premiums, and collecting the benefit when the insured person …
Bitcoin economics matter for American Bitcoin (NASDAQ:ABTC) because the company'sBusinessis built directly around the cryptocurrency: it mines new bitcoin using specialized computing hardware and holds a portion of what it produces as a treasury asset rather than selling it all immediately. That structure means …
Mining efficiency is the whole investment case for Abits Group (NASDAQ:ABTS) because, as a smaller mining operator, the company doesn't have the scale advantages of major diversified miners. Its profitability depends on how much it costs to extract and process each unit of output …
Hepatitis B research matters for Arbutus Biopharma (NASDAQ:ABUS) because the company has built its pipeline around one of the largest unmet needs in infectious disease: chronic hepatitis B affects hundreds of millions of people worldwide, yet existing treatments largely suppress rather than cure the …
Clinical data, not sentiment, will decide Acumen Pharmaceuticals (NASDAQ:ABOS) because the company is a clinical-stage biotechnology firm with no approved products and no product revenue. Its entireInvestmentcase rests on whether its lead antibody candidate, sabirnetug, can demonstrate a meaningful clinical benefit in Alzheimer's disease.
Lending conditions shape Arbor Realty Trust (NYSE:ABR) because, unlike a typical real estate investment trust that owns buildings and collects rent, Arbor is a mortgage REIT: it originates, services, and invests in loans secured by commercial and multifamily real estate. Its income comes from …
Absci (NASDAQ:ABSI) represents an attempt to apply artificial intelligence to one of biology's hardest problems: designing new medicines. Rather than discovering antibodies by screening vast numbers of natural candidates, Absci's platform uses AI models to design new antibody and protein sequences with desired properties, …
Abbott Laboratories (NYSE:ABT) links investors to everyday healthcare innovation because its products touch patients and consumers across the whole spectrum of medicine, from the hospital to the home. It makes continuous glucose monitors worn by people with diabetes, devices that treat heart-rhythm and structural-heart …